(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today applauded Food and Drug Commissioner (FDA) Scott Gottlieb’s call to publish a list of off-patent drugs that are vulnerable to price hikes, along with reviewing ways the agency can intervene when brand-name drugmakers use risk evaluation and mitigation strategies (REMS) to block generic competition.

“As the Trump administration seeks to combat high drug costs, we applaud FDA Commissioner Gottlieb’s decision to publish a ‘watch list’ of off-patent drugs.  This move, which PCMA and others have long advocated, will help deter manufacturers from buying the rights to drugs like Daraprim for the explicit purpose of raising their price,” said PCMA President and CEO Mark Merritt.